Webinar: Optimised workflow for rapid identification of neutralising antibodies against viral particles
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
The timeline to identify and develop clinically effective neutralising antibodies against viral particles from bench to patient is 18 to 24 months. In this webinar, Molecular Devices scientists demonstrate the steps from clonal selection to cell growth tracking to image-based assurance of monoclonality and show how, using a combination of CloneSelect instruments and screening platforms, the timeline for preclinical development of effective neutralising antibodies can be significantly shortened.
Related content from this organisation
- Patient-derived organoids in disease modelling
- The role of CRISPR in microbiome engineering breakthroughs
- Episode 15 – Minimise variability issues in your organoids
- Episode 14 – Complex assays with Ian Shoemaker, Beckman Coulter Life Sciences & Dr Oksana Sirenko, Molecular Devices
- Episode 12 – ELISA assays with Dr Ana Miletic and Anna Dey, Kyowa Kirin & Dr Cathy Olsen, Molecular Devices